investorscraft@gmail.com

Intrinsic value of AcelRx Pharmaceuticals, Inc. (ACRX)

Previous Close$0.23
Intrinsic Value
Upside potential
Previous Close
$0.23

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh0 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %-48.0NaN
Revenue, $3NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m39NaN
Operating income, $m-36NaN
EBITDA, $m-34NaN
Interest expense (income), $mNaN
Earnings before tax, $m-35NaN
Tax expense, $m0NaN
Net income, $m-35NaN

BALANCE SHEET

Cash and short-term investments, $m52NaN
Total assets, $m78NaN
Adjusted assets (=assets-cash), $m26NaN
Average production assets, $m23NaN
Working capital, $m37NaN
Total debt, $m104NaN
Total liabilities, $m114NaN
Total equity, $m-36NaN
Debt-to-equity ratio-2.895NaN
Adjusted equity ratio-2.957NaN

CASH FLOW

Net income, $m-35NaN
Depreciation, amort., depletion, $m2NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-30NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-3NaN
Free cash flow, $m-27NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m37
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount